ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution
(World News Science)

September 22, 2020 ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution Westport, CT, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices Added 2 new Principal Investigators for the ongoing Phase 2 trial expanding the total number of locations to 10 Contract Manufacturing Organization (CMO) appointed to manufacture Phase 3...